MeiraGTx Holdings plc MGTX on Thursday announced an asset purchase agreement with Janssen Pharmaceuticals Inc, a Johnson & Johnson JNJ company, for the remaining interests in botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for X-linked retinitis pigmentosa (XLRP).
MeiraGTx will monetize potential future royalties and milestones related to bota-vec, with J&J acquiring the remaining rights for developing, manufacturing, and commercializing bota-vec.
MeiraGTx is to receive $130 million in upfront and near-term milestone payments, including $65 million at signing, an additional $50 million anticipated in the first quarter of 2024, with the remaining $15 million in milestone payments expected later in 2024.
The company will receive up to an additional $285 million in cash payments upon first commercial sales of bota-vec in the U.S. and EU and for manufacturing technology transfer.
J&J will be responsible for any royalty or milestone amounts payable on bota-vec to UCL Business plc (University College London).
MeiraGTx has also entered into a commercial supply agreement with J&J for bota-vec manufacturing.
In October, Sanofi SA SNY made a $30 million investment in MeiraGTx. It purchased 4.0 million ordinary shares at $7.50 per share.
Sanofi also received a right of first negotiation for the use of MeiraGTx's Riboswitch gene regulation technology for certain Immunology and Inflammation (I&I) and Central Nervous System targets, as well as for GLP-1 and other gut peptides for metabolic disease and MeiraGTx's Phase 2 Xerostomia program.
The deal and the Sanofi transaction would increase the company's cash runway to mid-2026.
Price Action: MGTX shares are up 22.50% at $6.02 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
